Skip to main content
Frontiers in Physiology logoLink to Frontiers in Physiology
. 2021 Sep 24;12:715611. doi: 10.3389/fphys.2021.715611

Role of Barrier Integrity and Dysfunctions in Maintaining the Healthy Gut and Their Health Outcomes

Shruti Panwar 1, Sapna Sharma 2,*, Prabhanshu Tripathi 3,*
PMCID: PMC8497706  PMID: 34630140

Abstract

Mucosal surface layers are the critical borders throughout epithelial membranes. These epithelial cells segregate luminal material from external environments. However, mucosal linings are also accountable for absorbing nutrients and requiring specific barrier permeability. These functional acts positioned the mucosal epithelium at the epicenter of communications concerning the mucosal immune coordination and foreign materials, such as dietary antigens and microbial metabolites. Current innovations have revealed that external stimuli can trigger several mechanisms regulated by intestinal mucosal barrier system. Crucial constituents of this epithelial boundary are physical intercellular structures known as tight junctions (TJs). TJs are composed of different types transmembrane proteins linked with cytoplasmic adaptors which helps in attachment to the adjacent cells. Disruption of this barrier has direct influence on healthy or diseased condition, as barrier dysfunctions have been interrelated with the initiation of inflammation, and pathogenic effects following metabolic complications. In this review we focus and overview the TJs structure, function and the diseases which are able to influence TJs during onset of disease. We also highlighted and discuss the role of phytochemicals evidenced to enhance the membrane permeability and integrity through restoring TJs levels.

Keywords: tight junctions proteins, metabolic disorders, phytochemicals, membrane integrity, intestinal epithelial barrier

Introduction

The gastrointestinal inner membranous arrangements sketch out the human body's principal boundary with the outside world. The epithelium permits the nutrient absorption, supporting a physical barrier to the dispersal of proinflammatory components, like microorganisms, foreign antigens and toxins from the luminal milieu to the adjoining mucosal tissues (Groschwitz and Hogan, 2009). The epithelial membrane constructs selective permeability by either transcellular or paracellular methods. In transcellular mode of permeability, micronutrients such as carbohydrates (like glucose, hexose, and fruits etc.), amino acids, small size proteins, fatty acids, minerals, and vitamins are absorbed and transported. Specific channels or transporters situated on upwards (apical) and downwards (basolateral) sides of cell membranes plays a crucial role due to impermeability of membrane (Kapus and Szászi, 2006). In contrast, the paracellular mode is related with transport through the intercellular gaps among the bordering epithelial cells. This is controlled by combination of adherence junctions (AJs) and tight junctions (TJs) forming the junctional complex (Kiela and Ghishan, 2009; Suzuki, 2013). TJs are compulsory for maintaining a barrier among different sections of the body. The primary function of these TJs are to act as interstitial space for entry limiting the charge and size-based diffusion. Selective paracellular diffusion is a vital mechanism for the continuous homoeostasis among tissues. TJs have not studied on functional levels and considered as most mysterious of all adhesion complexes and have limited molecular and functional investigations due to their complex structures. In recent years proteins associated with tight junctions have been identified with different functions. These studies have confronted the conventional model where the tight junctions were considered to be merely a barrier controlling the diffusion of macromolecules. In addition to multiple functions, tight junctions are also associated with several human diseases especially due to their mutations at genetic level. Furthermore, tight junctions encounter countless viruses, bacteria, and foreign antigens, they affect functional and signaling behavior of TJ components for crossing the barriers. TJs are considered as preserved feature, with their biological functions across the vertebrate during evolution. The main objective of this review is to comply the current inventions about the biological functions of tight junctions and their role in various metabolic disorders. We discussed the understanding of how tight junctions regulates as signaling strategy that reflects the cellular response toward disease progression.

Cellular Constituents of the Mucosal Barrier

The main concern for barrier function at mucosal surfaces inhabits with the plasma membrane of epithelial cells, which is resistance to many hydrophilic solutes due to lack of specific transporters. There are many direct exposures which induce damage to epithelial cell for example, mucosal antigens or cytotoxic agents, such as drugs used for chemotherapy during cancer treatment result in a significant loss of barrier function. Along with the existence of a firm epithelial monolayer, the paracellular pathway between cells must be preserved and functions well. This function is regulated by the apical junctional complex, an assembly of the tight junction and adjacent adherens junctions (AJs) (Figure 1). The adherens junctions and the desmosomes give robust connective integrity among the epithelial cells. They also encourage intercellular interactions, but cannot regulate paracellular permeability (Brooke et al., 2012). The tight junctions are present on the apical side of the epithelial cell membrane and regulates the solute permeability paracellularly (Lee, 2015). In this respect, the tight junctions offer dual role, barrier as well as a pore, which are generated for the permeation of tiny molecules. Tight junctions are protein multiplexes composed of different proteins such as transmembrane proteins, claudins, occludins and lots of proteins in the cytosol. There are several extracellular stimuli that alter TJ barrier functions and paracellular permeability and are linked with disease vs. healthy conditions (Harhaj and Antonetti, 2004). Compromisation in tight junction barrier with augmented paracellular permeability result in translocation of proinflammatory factors in the lumen, encouraging mucosal immune activation, which subsequently lead to tissue injury and inflammation. Scientific studies and clinical observations suggest that the intestinal barriers including TJs and AJs have crucial role in in the pathogenesis and progression of intestinal as well as systemic diseases (Buckley and Turner, 2018). Under pathophysiological circumstances, pro-inflammatory cytokines, foreign antigens, and harmful microorganism contribute to barrier diminishing (Chelakkot et al., 2018). On the other hand, many food factors and nutrients also added in intestinal TJ regulation, and few possibly developed as prophylactic and therapeutic tools for compromised barrier-related disorders (Bischoff et al., 2014). TJ barrier integrity and permeability in in vitro models are measured by determining transepithelial electrical resistance (TER) and the strength of paracellular channels for small molecules like mannitol, dextran, and inulin was studied using permeability efflux. This review covers the structural component of apical junctional complex and summarizes the role of tight junction in regulating the barrier permeability and its relation with health consequences. This review also discusses about the selective participation of phytochemicals among intestinal TJs in well-being and disease progression.

Figure 1.

Figure 1

Classical overview of epithelial tight junction's structure in healthy conditions.

Structural Overview

TJs are manifold protein multiplexes positioned on the intestinal epithelial cell membrane at the apical side (Figure 1). They control paracellular permeability by regulating the passage of water, ions, and other solutes. TJs act as a boundary for macronutrient like lipids and proteins between basolateral and apical side of plasma membrane by blocking their free diffusion, this and preserve the cell polarity (Anderson and Van Itallie, 1995). There are four integral proteins, popularly known as occludin (Cummins, 2012), claudins (Krause et al., 2008), junctional adhesion molecule (JAM) (Ebnet et al., 2004), and tricellulin (Koval, 2017), among them claudin family comprising almost 24 more members. The neighboring cells form the barrier by hemophilic and heterophilic communications with the help of extracellular domains of transmembrane proteins (Tsukita et al., 2001; Ding et al., 2013). The intracellular domains of the transmembrane proteins cooperate with complex proteins in the cytosol, like zonula occludens (ZO) which further binds the transmembrane proteins to the internal junctional actomyosin ring. This interaction between TJ proteins along with actin cytoskeleton is necessary for the TJ structural upholding and functionality of TJs. Myosin light chain (MLC) activity (phosphorylation) regulates the circumferential narrowing and firmness of the perijunctional actomyosin ring (Cunningham and Turner, 2012). Kinases like Rho-associated kinase (ROCK) and myosin light chain kinase induces the MLC phosphorylation which leads to contraction of the actomyosin ring, subsequently opening the paracellular pathways. This segment recapitulates the structures and roles of the integral TJ proteins (Du et al., 2016; Jin and Blikslager, 2020).

Peripheral Membrane Adapter Proteins

Zona Occludin

The ZO proteins were the primary to be studied as TJ-specific proteins, till now three isoforms exists, popularly known as ZO-1, ZO-2, and ZO-3 (Itoh and Bissell, 2003). Sequence resemblance analysis, determined that ZO proteins belongs to the membrane-related guanylate kinase homolog family (González-Mariscal et al., 2000). They are multiple domain proteins comprising three post-synaptic Z domains, a Src homology-3 domain and a area of homology to guanylate kinase adjacent to N-terminus (Heinemann and Schuetz, 2019). These multiple domain assemblies deliver an inner cellular framework in the TJs and are crucial for regulation and structural preservation of TJ structure. As illustrated in Figure 1, the ZO proteins associate with other proteins, like actin and its related proteins to establish a solid framework for maintenance of membrane integrity. Previous reports stated that there are mutual interactions among ZO-1, ZO-2, ZO-3, but interestingly ZO-2 and ZO-3 do not interact with individually (Paris et al., 2008). ZO-1 coordinates with ZO-2 and ZO-3 within the cell, in the presence of the another PDZ domain, PDZ behave as a primary domain in anchoring receptor proteins within the membrane to internal cellular structural components (Umeda et al., 2006). There are reports that in MDCK cells, tight junction comprises of ZO-1 resides together with both ZO-2 and ZO-3. Even ZO-1 and ZO-2 combines with each other, the presence of ZO-1 interacts to a ZO-3 affinity column does not show the holding of ZO-2, thus demonstrating that ZO-1 does not engage ZO-2 with ZO-3 (Nomme et al., 2015). Among the ZO proteins, ZO-1 is the most studied protein in last two decades. ZO-1 confines to the promising cellular interaction both in in-vitro models as well as in in-vivo models (Tornavaca et al., 2015). Hence, it has been recommended that ZO proteins may facilitate the primary assembly of TJ proteins into cell-cell contacts. Till now, exhaustive attempts were performed to explore the structural role of ZO proteins but the functional role is still not clear. Although several researches have made attempts their attempts to confirm its function in ZO-1 deficient cells (Guillemot et al., 2008). They have created epithelial cells deficient of both ZO-1 genes and these ZO-1-deficient clones are still able to express healthy TJ structures and exhibited regular permeability; however, noticeable pause in the formation of TJ assembly comprising occludin and claudins was detected, demonstrating that ZO proteins have an imperative responsibility in initiation and regulation of this complex assembly (Umeda et al., 2004).

Integral Membrane Proteins

Occludin

Occludin, the foremost recognized module of tight junction threads was discovered by Furuse et al. (1993) and named after the Latin word “occlude.” Structural analysis of membranous protein determined that it consists of 4 hydrophobic membrane bridging domains, two extracellular 44 amino acid loop and two intracellular domains. The initial extracellular loops of amino acid arrangements are primarily rich in two residues namely, glycine and tyrosine. Sequencing provides more decisive evidence about the occluding structure. It is assumed that almost, two extracellular loops have 60-kDa tetraspan membranous protein whereas, a small intracellular turn, and cytoplasmic domains having N- and C-terminal (Furuse et al., 1993). The entire NH2 terminal which is half of the occludin protein, is categorized into five different domains (domains A-E). The half portion of –COOH terminal also known as domain E in cytoplasm is comprised of ~250 amino acids, constrain and is highly enriched with charged residues (Furuse et al., 1994). Among these extracellular loops about 60% are extremely rich in amino acids such as glycine and tyrosine and minimally are charged amino acids. In a same way the C-terminal regions are rich in amino acids such as threonine, serine and tyrosine. These amino acids are commonly phosphorylated by several type of protein kinases which are present in both the sides (apical as well as basolateral) of the cells (Sallee and Burridge, 2009). Additionally it was also documented that, the C-terminal sequence was bounded directly to ZO-1 protein (Tornavaca et al., 2015), which indirectly links with the actin cytoskeleton (Odenwald et al., 2017). Though, occludin isoforms have been seen (Mok et al., 2013), and there is no clear variance in their tissue distribution and functions has been demonstrated yet. Its expression co-relates to a lot many pathological diseases including diabetes which is associated with gut channels (de Kort et al., 2011). Diabetic rats experienced lowered expression of occludin levels but no change was found in ZO-1 levels (Chehade et al., 2002). It has also been associated with blood-retinal high VEGF, since the increase in permeability was observed due to the lowered expression of occludins (Antonetti et al., 1998).

Claudin

Claudins are family of proteins along with occludins that forms the most significant structural part of TJ complex zona occludins. Claudins word originates from “Claudere” which indicates near. They maintain the cell-cell connection among plasma membranes of nearby cells and to regulate the para cellular flow of ions (Krause et al., 2008). Claudins are ~25 kD transmembrane protein, reach over the membrane four stages and lies within both N & C terminal within the cytoplasm (Rüffer and Gerke, 2004). The claudin protein family in mammals constitutes 27 proteins that are essential for maintaining paracellular barrier in membrane of epithelial cells. All the members of claudin family consists of similar common structural skeleton, consisting cis- and trans- interactions among them but have diverse extracellular regions that are responsible for different functions in creating paracellular paths and channels. Human claudins are composed of approximately more than 300 amino acids which have a molecular weight varing from 21 to 34 KDa (Günzel and Yu, 2013). The basic structure of claudins have an intracellular short –NH2 terminus (except for claudin−5,-16, and−25), a long intracellular –COOH terminal, 2 extracellular loops (ECL1 and ECL2) and one tiny intracellular loop. The predicted ECL1 resides between the first uppermost and second layer of transmembrane helices and is a sustained loop of ~42–56 residues. It forms the lining of paracellular pore for transport of small ions due to its charge selectivity property. ECL1 also contains a conserved signature sequence of GLW which may play an important role in claudin structure stabilization and hence stabilizing trans interactions (Krause et al., 2009). ECL2 has a conserved amino acid sequence and is important for trans interactions. Claudins are organized in membrane as 4 transmembrane proteins that contain two extracellular parts (ECS1 and ECS2 in mouse claudin-15) arranged in beta sheets of five elements (β1–β5) adjacent to the upper surface of membrane. The extracellular beta sheet becomes stable with consensus motif, delivers an interface for intracellular adhesion. Claudins presents in adjacent cells have variable regions V1 and V2 and are important for communication. The cis interaction is hydrophobic in nature and provides the protrusion of extracellular helix and pocket of the extracellular region of transmembrane 3 (TM3) of neighboring claudin molecule is known to form the claudin cis-polymerization resulting in tight cell-cell adhesion. Claudins are pore proteins depending on variability in epithelial ionic permeability which is measured in terms of transepithelial electrical resistance (TEER). They play a crucial role in charge- and size- selective conductance of molecules in a paracellular manner. It is an important constituent of TJs and is known to have altered expression in different pathological conditions. One such example is diabetes which is accompanied by oxidative stress and hyperglycemia and, which is a main cause of damage in kidney. Diabetic renal damage is a popular complication and includes different functional variations such as natriuresis (Komers and Cooper, 1996), hyperfiltration (Mogensen, 1971) andproteinuria (Najafian and Mauer, 2009). Proteinuria is used as an early marker for detection of diabetic nephropathy (Najafian and Mauer, 2009). In one of the studies, it has been demonstrated that claudin-5, a constituent of glomerular barrier was shown to have decreased expression which might be the reason of early proteinuria in diabetic condition. On the other hand nitration of claudin-2 was shown to be a novel mechanism for increased natriuresis in diabetic rats (Molina-Jijón et al., 2014).

JAMA

JAM is a 40 KDa molecule which was first identified using monoclonal antibodies raised against endothelial cells (Martìn-Padura et al., 1998), albeit it is also present in epithelial cells. JAM- type A, type-B, and type–C belong to an immunoglobulins family and are type 1 transmembrane proteins containing extracellular immunoglobulin (Ig)- like (distal domain-D1 and proximal domain-D2), single transmembrane spanning domain, and a cytoplasmic domain which ranges from 40 to 48 amino acids. They have two common structural motifs necessary for biological activity. The first motif is present in the Ig domain D1 and has a signature tripeptide containing two differently charged residues of amino acid detached with hydrophobic amino acids. For JAM type-A, this motifs facilitate homodimerization in cis, through formation of salt bridges by differently charged amino acids in the among two monomers (Ebnet, 2017). The structure of JAM type-A crystal also expects the presence of additional residues in D1 domain responsible for cis-dimerization. All the three JAM proteins consist of –COOH terminus at canonical PDZ domain which forms network with several other scaffolding proteins such as ZO type-1, ZO type-2, Afadin, Par3, and MUPP1 to assemble signaling complex. Epithelia forms a barrier to avert flow of water, tiny molecules and microbes across epithelia layers. The important structure at epithelial tight junctions accountable for maintaining barrier function is Tight Junctions (TJs). JAM-A is rich in Epithelial cells, but not specifically restricted at TJ. The magnitude of JAM-A in maintaining epithelial barrier and paracellular permeability for tracers is well-understood. These specific functions are mediated by localization of serine 285 phosphorylated pool of JAM type-A at junctional point after setting up mature cell-cell contacts through interaction of PAR-αPKC complex and spot like adherens junctions (pAJs).

E-Cadherin

Cadherins are the part of calcium dependent cell surface adhesion protein family. Classical cadherins such as N-, P-, and E- cadherin were first identified in vertebrates (Takeichi, 1988), known to be localized in adherence junction to form an adherence belt and build an interaction with actin containing cytoskeleton. The human E-cadherin is a glycoprotein of molecular weight of 120 KDa which is transcribed by CDH1 gene, located on the chromosome 16q22. It is constituted by a transmembrane segment, one large extracellular domain, and a short cytoplasmic domain. There are five tandem repeats of 100 amino acids comprising an extracellular domain and among them N-terminal repeat has the largest part with adhesive functional activity.

Such portions of the molecule possess sites for calcium binding. The cytoplasmic tail interrelates with cytoskeleton framework through actin proteins such as alpha-, beta-, and gamma- catenins and is functionally important as it supports cadherin clustering and provides adhesive support (Shapiro and Weis, 2009). Cell-cell adhesion is important for providing a physical anchorage system to form a stable and highly organized tissue structure. Also, these contacts allow for effective intercellular communication and establish transmission though intracellular pathways with the help of macro and micro molecules present in plasma membrane. E-cadherin is primarily involved in formation of adherens junction and thus plays a crucial role in establishing the homeostasis of the healthy adult epithelial tissue for structure and integrity balance (van Roy and Berx, 2008). It has been reported that soluble E-cadherin, found in patient's urine with diabetic nephropathy and can act as a potential biomarkers for its early detection. The marker was identified using a proteomic based analysis of urinary E-cadherin of patients having type 2 diabetes with normo-albuminuria microalbuminuria, macroalbuminuria and is upregulated 1.3-, 5.2-, and 8.5-folds, respectively as compared to control group (Jiang et al., 2009). In another study of maturity-onset diabetes of the young population, it has been observed that pancreatic islets show abnormal framework and lowered expression of E-cadherin. E-cadherin mediates cell adhesion which is responsible for eliminated glucose which further leads to upregulation of intracellular calcium and insulin secretion, indicating that impaired insulin secretion is due to loss of E-cadherin (Yamagata et al., 2002).

Cingulin

Cingulin (140 kDa) is an internal protein of the TJs and recognized as a cytoskeleton-related actin protein. Investigators claimed that these proteins form a homodimer with huge N-terminal head and tiny globular C-terminal tail with coiled rod domain (Citi et al., 1991). Previous reports demonstrated that cingulin is located at the internal side of TJs and interact with many other TJ proteins, representing its part in TJ complex through GATA-4 signaling (Guillemot et al., 2013). Though its functional position is not known completely, studies has shown that the head domain connects with ZO proteins (Hou, 2019). In addition, in vitro binding assay discovered that there is a direct binding to occludin and JAM-A (Ebnet et al., 2004). Reports have also demonstrated that disruption of the gene for cingulin doesn't prevent the formation of tight junction rather alter the expression and levels of protein (Guillemot et al., 2004).

Clinical Significance of Intestinal TJs Proteins in Metabolic Diseases

The intestinal epithelial TJs create a corporeal fence against luminal antigens and molecules such as pathogenic bacteria, toxins, and food allergens. Higher diffusion of such molecules over the distorted barrier can result in pronounced initiation of inflammation and immune system. Consequently, barrier deficiency is carefully linked with the pathology of various gastrointestinal and systemic inflammatory disorders. Although various elements are engaged in disease initiations, barrier dysfunction can be one of the consequences leading in the direction of disease progression. Evidence from past two decades on basic scientific and clinical research suggest that barrier dysfunctions can play important role in the initiation and disease progression. This final portion of this review focusses on experimental studies about the association of intestinal TJ barrier dysfunctions and disease development and progression.

Possible Role of TJs in Different Disease Conditions

IBD

Includes many gastrointestinal disorders such as ulcerative colitis and crohn's disease. IBD progresses with intensive inflammation due to affected barrier integrity which may lead to the mislaying of solutes and essential fluids beyond the barrier. This results in high amounts of antigen translocation which is the major reason of immune cells flux and inflammation causing the barrier to disrupt further (Holmberg et al., 2018). Ulcerative colitis and crohn's disease are linked with high rate of loss of epithelial cell through apoptosis (Di Sabatino et al., 2003) which relates the immune response to cell death. Constituents of epithelial barrier affected in such diseases are TJs, mucusal layer, and antimicrobial peptides.

Crohn's Disease (CD)

Increased expression of Claudin 2 and reduced redistribution of Occludin, Claudins like−3,−5,−8. Cytokine profile consists of TNF alpha, IFN gamma (Th 1). High rate of epithelial apoptosis is seen (Zeissig et al., 2007). Observation of thickness in mucus layer accompanied with abnormal PTM's of mucins (Strugala et al., 2008). Lack of expression of Human beta defensin 2&3 (Wehkamp et al., 2002). Expression of antiprotease are also reduced (Schmid et al., 2007).

Ulcerative Colitis (UC)

High levels of Claudins-2 expression (Luettig et al., 2015) and redistribution of Occludins, Claudins like−1,-4,-7. Cytokines mainly includes IL-13 and TNF alpha (Th 2) (Heller et al., 2005). This has also shown high apoptotic foci in epithelium. Mucus layer is almost diminished, very low goblet cells (Strugala et al., 2008), lowered expression of MUC2 &3 (Wibowo et al., 2019). Presence of HBD-2,3&4 (Fahlgren et al., 2004), increased levels of antiproteases (Schmid et al., 2007).

Cardiovascular Disease (Atherosclerosis)

Clinal studies on the patients suffering from atherosclerosis had altered junctions indicating a relation between cell junctions and atherosclerosis. Tight junction pathway was upregulated which significantly upregulates the expression levels of claudin−1, occluding, and ZO-1. Connexin 43 (Cx43) and 46 were also significantly increased. Earlier published study enlightens the fact that upregulated Cx 43 lead to monocyte adherence to vascular endothelial cells progressing further into atherosclerosis (Yuan et al., 2015). Cx 45, 46 exhibit synergetic associations and follows the similar pattern as Cx 43. Altered tight junction protein expression led to changed phosphorylation states. Regulation of the expression of ZO1 and occludin via myosin kinase inhibitor and its phosphorylation improved the atherosclerosis state in high fat fed rabbit model (Zhu et al., 2013). Proteins involved in SMAD pathway and TGF-β/endoglin levels were lowered in patients with atherosclerosis (Chen et al., 2017).

Gastric Cancers

Tight junctions have played specific role in cancer development (Table 1).

Table 1.

Summarizes the role of various TJ in cancer.

Type of cancer Downregulation References Upregulation References
Colorectal carcinoma Claudin 4,7 ZO- 1 Claudin 8 Suren et al., 2014 Kaihara et al., 2003 Grone et al., 2007 Claudin 2 Claudin 1 Occludins Claudin 12 Buhrmann et al., 2015 Sun et al., 2015 Grone et al., 2007
Gastric cancer Claudin 17 Gao et al., 2013 Claudin 1 Claudin 4 Huang et al., 2014 Hwang et al., 2014
Hepatocellular carcinoma Claudin 11 Claudin 14 Németh et al., 2008 Akizuki et al., 2017 Claudin 1 ZO-1 Claudin 11 Suh et al., 2013 Ram et al., 2018
Breast cancer Claudin 1 ZO 1 ZO 2 Kim et al., 2008 Morohashi et al., 2007 Hoover et al., 1998 Chlenski et al., 2000 Claudin 3 Claudin 4 Claudins 20 Jaaskelainen et al., 2018 Jiwa et al., 2014 Martin et al., 2013
Lung cancer Claudin 18 Claudin 7 Akizuki et al., 2017 Kudinov et al., 2016 Claudin 10 Zhang et al., 2013
Pancreatic cancer ZO 2 ZO 1 Chlenski et al., 1999 Hoover et al., 1998 Claudin 4 Long et al., 2001
Renal cancer Claudin 16 Buhrmann et al., 2015

Diabetes Mellitus (Type 1)

Hypothesized mechanism supports that the high gluten diet favors the increased colonization of Bacteriodes (Fasano et al., 1991) causing dysbiosis and zonulin pathway activation (Mowat, 2003). Food antigens such as wheat gluten (gliadin) can bind to CXCR3 intestinal epithelia leading to MyD88-activated zonulin pathway which further can cause increase in intestinal permeability (Fasano, 2001). Zonulin pathway activation leads to higher level of zonulin release (Visser et al., 2009) which then bind to its receptor present at intestinal epithelium and disassembles the tight junctions and also causing the phosphorylation of occludin, ZO-1 and alterations in occludin-ZO-1 and ZO-1- proteins interaction and polymerization of actin proteins (Bjorkman et al., 1987a). Disbursement of tight junctions assembly allows the entrances of luminal antigens which are then managed by immune cells like antigen presenting cells of lamina propria and presented to T cells (Bjorkman et al., 1987b). These events later on leads to autoimmune diseases i.e., Type 1 diabetes (Cuvelier et al., 1990). These data demonstrate that loss of gut barrier integrity is not only a contributor in T1D pathogenesis but a factor in causing chronic DSS-colitis triggering T1D in TCR-tg BDC2.5XNOD mice that otherwise do not develop diabetes. BDC2.5XNOD mice do not become diabetic despite having circulating T cells specific for an islet antigen. Exogenous events like a viral infection causes the disturbance in islets environment and leads to inflammation leading to tissue damage (Horwitz et al., 1998). Disturbances like the bacterial translocation though the compromised gut barrier induces the islet damage.

Obesity

Direct association has been established between obesity and permeability of intestinal epithelium. Experiments on obese mouse model such as ob/ob mice and db/db mice have shown the signs of altered tight junctions (Brun et al., 2007). These homozygous mice possess an increased levels of proinflammatory cytokines INFγ, IL-6, IL-1β, and TNF-α in comparison to wild-type control mice. Studies had revealed that the diet induced obesity (DIO) also lead to reduced expression of TJ proteins (Cani et al., 2009; Suzuki and Hara, 2010). DIO also contribute in changing the gut bacterial population by effecting the tight junction permeability inducing LPS associated endotoxemia and increased inflammation (Cani et al., 2008; Rohr et al., 2019) which is one of the reason for resistance developed for insulin. Other studies have used leptin-deficient mice and have shown that gut microbiome dysbiosis also interrelated with reduced expression of ZO1, occludin and genes synthesizing mucin (Nagpal et al., 2018).

NAFLD

There is an intimate interaction between the gut microbiome and metabolism in liver. Gut derived substances are received by the liver through the portal system. Recent studies provide evidences that the bile acids produced by liver are taken up by bacteria (Ridlon et al., 2014). Studies have demonstrated that NAFLD patients have reduced barrier integrity (Miele et al., 2009). Compromised gut barrier leads to increased bacterial endotoxin (LPS) permeability, which then enters the portal system. LPS, bacterial outer membrane of a gram -ve bacteria which act as a effective inflammatory molecule when binds with corresponding TLR activates NFκB and MAPK signaling pathways (Yuan et al., 2017) induces inflammatory cytokines production such as IL-6 and TNF-α (Dai and Wang, 2015) which slowly progress to liver fibrosis and cirrhosis. It was proposed that a dysbiosed intestine might lead to endogenous ethanol production which can in turn interrupt the mucosal barrier and elevates the LPS levels in the systemic circulation (Malaguarnera et al., 2014).

Management of Barrier Integrity During Pathological Conditions

There is a recent attraction toward the role of gut barrier in disease pathogenesis. Concede intestinal barrier integrity is noticed in both systemic as well as intestinal diseases and other metabolic disorders discussed above. Although, the researchers are still trying to explore how the alterations in barrier integrity and can affect the pathogenesis of several diseases. Pathological or ecological elements may be the decisive role to seize healthy functionality and enhancement in the barrier permeability. In future, it is essential to appreciate the aspects that subsidize the barrier integrity damage under diseased circumstances (Figure 2).

Figure 2.

Figure 2

Barrier integrity during diseased conditions.

Scientific evidences have shown the claudins play vital role in regulation of cancer. MAPK and PKC facilitated phosphorylation of claudin regulate the barrier functions (Bhat et al., 2019). PKA mediated phosphorylation allows the increased Mg2+ transport (González-Mariscal et al., 2008). Researches have demonstrated that claudins of colonic regions have perturbed phosphorylation in cases of colitis (Zhu et al., 2019). Blood vessel epicardial substance (BVES) functions in epithelial to mesenchymal transition through tight junction signaling pathways (Williams et al., 2011). Exposure to ozone in mice drastically increased claudin 3 along with cytokines and also reduced the levels of claudins 14 expression which establishes a co-relation between TJ and cancer (Kim et al., 2018). Claudin 2 overexpression was seen in patients suffering from colorectal cancer (Kinugasa et al., 2007) functions through EGFR signaling mechanism. Rabquer and colleagues have shown angiogenic role of JAM C (Rabquer et al., 2010). On the other hand, inactivation of p53 dependent pathway via notch 1 in HCT 116 could be reason for reduced apoptosis. Metastasis was seen in transgenic mice which exhibit increased expression of claudin 1 via notch signaling (Kim et al., 2007). PKC activation leads to claudin 1 overexpression resulting in invasion of cells via c-Abl-PKC signaling in liver cells (Yoon et al., 2010). Claudin 3&4 have been shown to enhance EMT in cancerous cells of ovary (Lin et al., 2013). ERK a kinase phosphorylates an array of proteins which might be involved in variety of functions like proliferation, survival, apoptosis, metabolism etc. Claudin 7 have been linked to contribute in metastasis of esophageal squamous carcinoma (Usami et al., 2006). EGFR and other several signaling pathways are linked with claudin 2 overexpression in lung cancer cell lines A549 (Ikari et al., 2012). Loss of barrier integrity is tightly associated with inflammation which in many cases progresses in cancer. Inflammation could be the reason for increased paracellular permeability and flux of immune cells which then contribute in release of proinflammatory cytokines (Al-Sadi et al., 2009). These proinflammatory cytokines in-turn induces the changes in TJ proteins in a loop and also promote survival of cancer cells. Influx of immune cells releases ROS which induces mutations in cells by causing DNA damage and might also inactivate mismatch repair (Kidane et al., 2014). Cancer is affiliated to immune cells by production of ROS, supporting angiogenesis and metastasis, all of this involves many pathways like COX-2, IL-6/STAT3, NF -kB, TNFα, Th17 signaling but there is still a need to revisit the links to get a better understanding about the TJs and their role in cancer.

Role of Dietary Plant Components in TJs Maintenance

Present medication strategies in the health system include chemically synthesized antivirals, antibiotics, steroids, inhibitors and many more. From past two decades there are attraction toward natural compounds derived from plant parts from past 2 decades. Although, safety concern of such agents is parallelly emerging however, they are very cost effective and their availability in local region are the benefits of these new drugs. Phytochemicals is very wide term used to describe many compounds derived from herbal products or plants with therapeutic values toward health with low toxicity/side effects. Despite few clinical trials in patients, phytochemicals are generally recognized as safer substitute from the typical conventional remedies. Among all of them, most potential ones are terpenoids, saponins, organ-sulfides, alkaloids, lignans, and polyphenols. They possess abundant health benefits including detoxifying enzyme modulation, antimicrobial activities, immune system stimulation, antioxidant activities etc. thus possess lots of capability to intervene in therapeutic significance (Lee et al., 2018). In this review article, we aimed to represent the studies performed in this area, primarily concentrating on phytochemical exhibiting favorable effects in the intestinal barrier enhancement together with their mechanistic events. The following sections will be discussing the role of different phytochemicals, their possible mechanism of action, and prospects.

Certain biologically active compounds plays a pivotal role in upholding the tight junction integrity (Kovacs and Mela, 2006). Phytochemicals and their secondary metabolites are potentially used in reduce the paracellular transport through tight junction is extensively reported (Lee et al., 2018).

Quercetin

Quercetin belong to flavonoid group and is reported to enhance the intestinal TJ barrier. The mechanism behind the action of Quercetin are transcription factors involved in enhanced expression of claudin 4 mediated by quercetin (Noda et al., 2014). Degraded products of quercetin such as 2,4,6,-trihydroxybenzoic acid and 3,4-dihydroxybenzoic acidalso enhances the expression of claudin 4 (Amasheh et al., 2009). Claudin 2 levels are reduced that restores the permeability induced by TNF-α by addition of quercetin in-vivo and in-vitro (Amasheh et al., 2012). Reports published focus on the reduction of inflammation and restoration of occludin and claudin (Shigeshiro et al., 2013). PI-3 Kinase cell signaling is inhibited by quercetin in the concentration dependent manner, since it is already established that this signaling is involved in cell proliferation (Agullo et al., 1997). ZO2, occluding and claudin 1 assembles in stimulus of quercetin by inhibiting the PKCδ activity in Caco-2 cells (Suzuki and Hara, 2009). 200 and 100 μM of quercetin have shown enhanced appearance of claudin-1&−4, ZO-2, occludin through the reduction of PKG (Amasheh et al., 2008) and PKCδ (Elias et al., 2009) activity, respectively on caco-2 cell lines. These studies directly correlate the effects of quercetin to maintain the barrier integrity. Quercetin significantly suppress MLCK activity (Suzuki and Hara, 2009). As evident by the above studies, quercetin regulates PKC activity and enhance the expression levels of TJs proteins indicating its tremendous potential in management of membrane integrity associated disorders.

Berberine

Berberin is an isoquinoline alkaloid used an ancient Asian medicine to treat gut allied problems (Zhang et al., 2011). Evidently the effects of berberine on membrane integrity has been studied cell models (in-vitro) and animal models (in-vivo). At the time of microbial sepsis membrane integrity is lost affecting specific TJ proteins, such as the integral membrane protein occludin (Furuse et al., 1993), zonula occludens (ZO) (Stevenson et al., 1986), and claudin family members (Furuse et al., 1999) and the opening of tight junction is controlled by myosin light chain kinase phosphorylation (Turner, 2006). Experiments on rat models demonstrated that LPS induced sepsis is lowered when MLCK is inhibited. Involvement of NFκB allows the increased expression of MLCK that stimulate the breakdown of TJ's (Ye et al., 2006). Other in-vitro studies have confirmed that berberine functions to the lower the expression of inflammatory genes by reducing NFκB signaling. Berberine mediate the inhibition by working on IκB kinase and stabilizing IκB factor. Type 2 diabetic rats have shown improvements when supplemented with berberine, significant improvements were seen on intestinal permeability (Gong et al., 2017). Lee et al. has shown that TJ health was enhanced when Caco-2 cell lines were supplemented with 100 μM of berberine (Lee et al., 2018). There are many studies conducted on berberine in different model systems showing their strong anti-inflammatory property. Berbarine supplementation increase the expression of major proteins of TJ complex, thus regulating the membrane permeability.

Curcumin

Curcumin is a polyphenolic compound which is found abundantly in turmeric commonly used as spices in Asian countries. It has anti-tumoural, healing and anti-inflammatory and anti-oxidative effects. It has been reported to show positive effects on reproductive, respiratory, cardiovascular and digestive health (Ali and Soheil, 2013). In a study when the caco2 monolayers were stimulated with proinflammatory cytokines like IL-6 and TNF apha (Ma et al., 2005), through NFκB signaling deteriorated the function of TJ but the pretreatment of curcumin abrogated this effect (Joe et al., 2004; Wang et al., 2017). Another mechanism of curcumin involves the suppression of IL-1β p38 signaling leading to inhibition of p38/(Al-Sadi and Ma, 2007) MAP Kinase resulting in MLCK inactivation, so phosphorylation did not take place on MLC maintaining the structural integrity of intestinal TJ (Gong et al., 2017). It is found that curcumin has capacity to reduced colonic histopathological score and colonic myeoperoxidases activity. It is also observed that phenolic compounds, and curcumin or rutin, can restored the length of colon significantly, in DSS treated models. These compounds can prevent mucosal injury and reduced neutrophil infiltration, perhaps due to antioxidative activity and inhibition of NF-κB activation (Wang et al., 2017). Curcumin is very popular from old days and till now it has been used in various medicinal formulation. The above-mentioned studies are strong enough to claim its role in clinical gastrointestinal complication. There is urgent need to explore the functionality of such compounds in systematic way to meet the requirements of multi targeted herbal drugs.

Kaempferol

Kaempferol belongs to flavonol and isabundant in common fruits and vegetables. They possess voluminous amounts of anti-oxidant and anti-inflammatory (Calderón-Montaño et al., 2011) components. Kaempferol is known to have positive effect in building the barrier integrity and TEER (Suzuki et al., 2010). A study demonstrated that kaempferol when given at concentration of 100 μM increased the TJ proteins like ZO1&2, Occludin, and Claudin 1, 3&4. It affects the organization of TJ proteins (Suzuki and Hara, 2010). Some studies demonstrate that it is also responsible for redistribution of lipid microdomain proteins like flotillin1 and caveolin1 (Nusrat et al., 2000; Suzuki and Hara, 2010) which are associated with TJ membrane integrity. Researchers demonstrated that Kaempferol swiftly and significantly elevated the TEER values of the Caco-2 cells, but surprisingly they did not disturbed the membrane permeability. However, due to increase in expression of TJ proteins there is advancement in the cell. In the same study, researchers observed that Kaempferol improved the expression levels of claudin-4, which is reported to decreases Na+ permeability (Suzuki et al., 2010). Clinicians have observed that psychological/physiological stresses and irritable bowel disease can lead to secretary diarrhea due to irregularity in intestinal ion secretion, including paracellular Na+ secretion (Suzuki et al., 2010; Calderón-Montaño et al., 2011). Kaempferol administration might provide an mitigative effect on diarrhea in such situations. Such findings shows that kaempferol might has capability to regulate the dysfunctions related to membrane permeability.

Genistein

Genistein is an isoflavone compounds and is a known inhibitor of protein tyrosine kinases (Akiyama et al., 1987). Phosphorylation of particular proteins response to arrangement and functioning of the tight junction (Sakakibara et al., 1997). Some studies demonstrate that the pretreatment of Caco-2 (Rao et al., 1997) enterocytes for time duration 30 min with 300 μmol/L genistein enhanced a H2O2-induced lowered TEER; this dose dependent effect. 300 μmol/L of Genistein blocked the opening of TJ barrier which prevented the influx of enteric bacteria (Lee et al., 2018). 300 μM of genistein reduced c-Src kinase induced oxidative stress and inhibited the phosphorylation of tyrosine present within the TJ proteins including occluding, zona occluden, E-cadherin and beta catenin which stabilized TEER. Combined treatment with a xanthine oxidase and xanthine induces the oxidative stress and elevate the labeled mannitol uptake in the caco-2 cell monolayers which represents the dysfunction junctional barriers could be reverted by the administration of genistein (Rao et al., 2002). A separate study shows that genistein showed a protective role against DSS fed mice and improved the barrier function. It also lowered cytokine expression while reducing the colonic inflammatory responses (Zhang et al., 2017). Genistein has also shown protection against acetaldehyde-induced model through intestinal TJ barrier function (Atkinson and Rao, 2001). It is assumed that the mechanism responsible for endotoxemia is due to the luminal acetaldehyde-induced damage of intestinal TJ barrier complex (Sheth et al., 2007). Genistein dose-dependent treatment prevented the acetaldehyde-induced intestinal permeability (Atkinson and Rao, 2001). Moreover, it is described that genistein improves the loss of intestinal TJ barrier function due to inflammation. However, the precise mechanisms underlying the genistein-mediated protective effects remain unclear and needs to be fully explore in future studies.

Naringenin

Naringenin belongs to flavanone group and present in citrus fruits. They safeguard the TJ by elevating the occludins levels, JAM-A and claudins-3 in a DSS diet induced colitis mice (Azuma et al., 2013). Introducing Naringenin elevated TJ barrier, immunoblot analysis in the studies clearly depicted the association of TJ with cytoskeletal components. Claudin-4 expression levels were elevated with activation of claudin-4 promoter with Naringenin treatment (Noda et al., 2013). Assembly of TJ proteins is indeed a crucial factor against diseases like CD and UC (Azuma et al., 2013), researchers studies that in human caco-2 cells, feeding of naringenin protect the TJ proteins due to DSS mediated changes in colitis model (Noda et al., 2012). Naringenin is reported to increase the structural assembly in TJs when supplemented to caco-2 cells (Suzuki, 2020). Additionally, evidence shows intestinal bacteria can metabolized naringin in the proximal part of colon, which results in further smaller phenolics molecules (Stevens et al., 2019). Naringenin and their metabolites can influence the composition of intestinal microbial population and might employ beneficial effects on barrier functions and inflammation in intestine. Although the precise mechanisms of action are not well-defined more investigations in human subjects are warranted.

Resveratrol

Resveratrol comes under stilbenoid group and is enormously present in grapes and peanuts. A study demonstrate that the effects induced by DSS fed colitis mice are alleviated by the diet rich in resveratrol and restoration of TJ proteins like ZO-2, occludin, JAM-A, claudins 3,4 and 7 was evident. Caco-2 treated with resveratrol have shown reduced production of IL-8 resulting in lowered infiltration of neutrophils and hence is at the center of resveratrol mediated (Mayangsari and Suzuki, 2018a). Resveratrol has shown alleviation for oxidative stress and IL-6 induced hyperpermeability (Azuma et al., 2013). Levels of IL-6 regulate the hyperpermeability of intestine epithelium as it increases claudin-2 expression that leading to pore formation via ERK1/2 and PI3K but introduction of resveratrol reduces the expression of IL-6 induced ERK 1/2 activation thereby lowering the expression of claudin 2 (Suzuki et al., 2011). Resveratrol showed a potential to regulate intestinal TJ barrier in dose dependant manner (50, 100, and 200 μmol/L) in in-vitro models (Mayangsari and Suzuki, 2018b). A study reports H2O2 facilitated loss of barrier integrity is due to the occludin expression upregulation via Tyr phosphorylation but the effects are restored by resveratrol (Mayangsari and Suzuki, 2018b). Others have reported to show the enhanced levels of c-Src regulating the phosphorylation of tyr residue 398 and 402 in occludin which in turn prevents the interaction of occludin with ZO-1 that results in destabilization of assembly of TJ (Elias et al., 2009). Even though information is still inadequate although it is assuring that resveratrol could be a useful agent for the treatment of gastrointestinal associated conditions.

Future Perspective

New interrogation need to be arranged in future for clinical management of TJs associated diseases, since it is new area to emphasize safety concern of existing therapy as well as discovering alternative therapies, parallelly with the introduction of novel drugs. Both the clinical studies as well as basic research have provided the evidences for alignment between increase in intestinal permeability and several metabolic diseases like type 2 diabetes, celiac disease and irritable bowel syndrome. Till now the existing literature supports the usage of phytochemicals compounds in clinical trials and mentioned their beneficial effects with good safety profile. Dietary phytochemicals supplementation possibly might offer a potential remedy for these disease condition. Recently the researchers have developed the interest for studying the mechanisms involving phytochemicals and enhanced barrier integrity and reduction in gut permeability. However, in most instances, presented data were from studies in in-vitro models. Moreover, whether the phytochemical's effects are directly involved in the development and maintenance of epithelial barrier or it is mediated via enhancement of TJ proteins is unclear. Thus, detailed in vivo and more mechanism oriented studies are required, which may originate the development of plant based preventive or therapeutic approaches to combat the diseases linked with barrier dysfunction. In addition, the literature from available studies suggest that the polyphenols perform their beneficial activities in TJ regulation via cross talk between multiple pathways. Further studies are required in future to establish the mechanisms involved in the interactions between phytochemicals and the signaling pathways providing the defensive/protective actions on barrier function and formation of intestinal TJs. Studying these pathways and their interconnections will help to recognize the usage of these phytochemicals in the treatment and prevention of defects in intestinal barrier functions and the related diseases or complications. In this review, we explore the different direction in which TJs can influence human health and to pay more attention toward phytochemicals in terms of therapeutics agents. However, evidence-based information about the phytochemical usage is still lacking behind and more clinical studies should be elucidated to study their role and optimal administration are needed.

Author Contributions

SS and PT: conceptualization, investigation, supervision, writing, reviewing, and editing. SP and SS: figure, formal analysis, and literature collection. All authors contributed to the article and approved the submitted version.

Funding

PT was supported from programme grant funding from Department of Biotechnology, Govt. of India (Ramalingaswami Fellowship), Science and Engineering Research Board (SERB), Govt. of India, and CSIR-Indian Institute of Toxicology Research, Govt. of India. SS was supported by a post-doctoral fellowship women (PDFW) awarded by the University Grant Commission (UGC, India). Both the authors had a significant role in content, structure, and review of manuscript. The CSIR-IITR manuscript number is IITR/SEC/2021-2022/40.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Agullo G., Gamet-Payrastre L., Manenti S., Viala C., Rémésy C., Chap H., et al. (1997). Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol. 53, 1649–1657. 10.1016/S0006-2952(97)82453-7 [DOI] [PubMed] [Google Scholar]
  2. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262, 5592–5595. 10.1016/S0021-9258(18)45614-1 [DOI] [PubMed] [Google Scholar]
  3. Akizuki R., Shimobaba S., Matsunaga T., Endo S., Ikari A. (2017). Claudin-5,−7, and−18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma. Biochim. Biophys. Acta 1864, 293–302. 10.1016/j.bbamcr.2016.11.018 [DOI] [PubMed] [Google Scholar]
  4. Ali N., Soheil A.-E. (2013). A review of therapeutic effects of curcumin. Curr. Pharm. Design 19, 2032–2046. 10.2174/138161213805289273 [DOI] [PubMed] [Google Scholar]
  5. Al-Sadi R., Boivin M., Ma T. (2009). Mechanism of cytokine modulation of epithelial tight junction barrier. Front. Biosci. 14, 2765–2778. 10.2741/3413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Al-Sadi R. M., Ma T. Y. (2007). IL-1beta causes an increase in intestinal epithelial tight junction permeability. J. Immunol. 178, 4641–4649. 10.4049/jimmunol.178.7.4641 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Amasheh M., Andres S., Amasheh S., Fromm M., Schulzke J. D. (2009). Barrier effects of nutritional factors. Ann. N. Y. Acad. Sci. 1165:267. 10.1111/j.1749-6632.2009.04063.x [DOI] [PubMed] [Google Scholar]
  8. Amasheh M., Luettig J., Amasheh S., Zeitz M., Fromm M., Schulzke J. D. (2012). Effects of quercetin studied in colonic HT-29/B6 cells and rat intestine in vitro. Ann. N. Y. Acad. Sci. 1258, 100–107. 10.1111/j.1749-6632.2012.06609.x [DOI] [PubMed] [Google Scholar]
  9. Amasheh M., Schlichter S., Amasheh S., Mankertz J., Zeitz M., Fromm M., et al. (2008). Quercetin enhances epithelial barrier function and increases claudin-4 expression in Caco-2 cells. J. Nutr. 138, 1067–1073. 10.1093/jn/138.6.1067 [DOI] [PubMed] [Google Scholar]
  10. Anderson J. M., Van Itallie C. M. (1995). Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 269, G467–G475. 10.1152/ajpgi.1995.269.4.G467 [DOI] [PubMed] [Google Scholar]
  11. Antonetti D. A., Barber A. J., Khin S., Lieth E., Tarbell J. M., Gardner T. W. (1998). Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 47, 1953–1959. 10.2337/diabetes.47.12.1953 [DOI] [PubMed] [Google Scholar]
  12. Atkinson K. J., Rao R. K. (2001). Role of protein tyrosine phosphorylation in acetaldehyde-induced disruption of epithelial tight junctions. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G1280–G1288. 10.1152/ajpgi.2001.280.6.G1280 [DOI] [PubMed] [Google Scholar]
  13. Azuma T., Shigeshiro M., Kodama M., Tanabe S., Suzuki T. (2013). Supplemental naringenin prevents intestinal barrier defects and inflammation in colitic mice. J. Nutr. 143, 827–834. 10.3945/jn.113.174508 [DOI] [PubMed] [Google Scholar]
  14. Bhat A. A., Uppada S., Achkar I. W., Hashem S., Yadav S. K., Shanmugakonar M., et al. (2019). Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk. Front. Physiol. 9:1942. 10.3389/fphys.2018.01942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Bischoff S. C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.-D., Serino M., et al. (2014). Intestinal permeability–a new target for disease prevention and therapy. BMC Gastroenterol. 14, 189–189. 10.1186/s12876-014-0189-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Bjorkman P. J., Saper M., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. (1987a). Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506–512. 10.1038/329506a0 [DOI] [PubMed] [Google Scholar]
  17. Bjorkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. C. (1987b). The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329, 512–518. 10.1038/329512a0 [DOI] [PubMed] [Google Scholar]
  18. Brooke M. A., Nitoiu D., Kelsell D. P. (2012). Cell–cell connectivity: desmosomes and disease. J. Pathol. 226, 158–171. 10.1002/path.3027 [DOI] [PubMed] [Google Scholar]
  19. Brun P., Castagliuolo I., Leo V. D., Buda A., Pinzani M., Palù G., et al. (2007). Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. 292, G518–G525. 10.1152/ajpgi.00024.2006 [DOI] [PubMed] [Google Scholar]
  20. Buckley A., Turner J. R. (2018). Cell biology of tight junction barrier regulation and mucosal disease. Cold Spring Harb. Perspect. Biol. 10:a029314. 10.1101/cshperspect.a029314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Buhrmann C., Shayan P., Kraehe P., Popper B., Goel A., Shakibaei M. (2015). Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem. Pharmacol. 98, 51–68. 10.1016/j.bcp.2015.08.105 [DOI] [PubMed] [Google Scholar]
  22. Calderón-Montaño J. M., Burgos-Morón E., Pérez-Guerrero C., López-Lázaro M. (2011). A review on the dietary flavonoid kaempferol. Mini Rev. Med. Chem. 11, 298–344. 10.2174/138955711795305335 [DOI] [PubMed] [Google Scholar]
  23. Cani P. D., Bibiloni R., Knauf C., Waget A., Neyrinck A. M., Delzenne N. M., et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes 57:1470. 10.2337/db07-1403 [DOI] [PubMed] [Google Scholar]
  24. Cani P. D., Possemiers S., Van de Wiele T., Guiot Y., Everard A., Rottier O., et al. (2009). Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103. 10.1136/gut.2008.165886 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Chehade J. M., Haas M. J., Mooradian A. D. (2002). Diabetes-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1) expression. Neurochem. Res. 27, 249–252. 10.1023/a:1014892706696 [DOI] [PubMed] [Google Scholar]
  26. Chelakkot C., Ghim J., Ryu S. H. (2018). Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp. Mol. Med. 50:103. 10.1038/s12276-018-0126-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Chen L., Chen Z., Ge M., Tang O., Cheng Y., Zhou H., et al. (2017). Monocytic cell junction proteins serve important roles in atherosclerosis via the endoglin pathway. Mol. Med. Rep. 16, 6750–6756. 10.3892/mmr.2017.7444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Chlenski A., Ketels K. V., Korovaitseva G. I., Talamonti M. S., Oyasu R., Scarpelli D. G. (2000). Organization and expression of the human zo-2 gene (tjp-2) in normal and neoplastic tissues. Biochim. Biophys. Acta 1493, 319–324. 10.1016/S0167-4781(00)00185-8 [DOI] [PubMed] [Google Scholar]
  29. Chlenski A., Ketels K. V., Tsao M. S., Talamonti M. S., Anderson M. R., Oyasu R., et al. (1999). Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. Int. J. Cancer 82, 137–44. [DOI] [PubMed] [Google Scholar]
  30. Citi S., Amorosi A., Franconi F., Giotti A., Zampi G. (1991). Cingulin, a specific protein component of tight junctions, is expressed in normal and neoplastic human epithelial tissues. Am. J. Pathol. 138, 781–789. [PMC free article] [PubMed] [Google Scholar]
  31. Cummins P. M. (2012). Occludin: one protein, many forms. Mol. Cell. Biol. 32, 242–250. 10.1128/MCB.06029-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Cunningham K. E., Turner J. R. (2012). Myosin light chain kinase: pulling the strings of epithelial tight junction function. Ann. N. Y. Acad. Sci. 1258, 34–42. 10.1111/j.1749-6632.2012.06526.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Cuvelier C., Mielants H., De Vos M., Veys E., Roels H. (1990). Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy. Gut 31, 545–549. 10.1136/gut.31.5.545 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Dai X., Wang B. (2015). Role of gut barrier function in the pathogenesis of nonalcoholic Fatty liver disease. Gastroenterol. Res. Pract. 2015:287348. 10.1155/2015/287348 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. de Kort S., Keszthelyi D., Masclee A. A. (2011). Leaky gut and diabetes mellitus: what is the link? Obes. Rev. 12, 449–458. 10.1111/j.1467-789X.2010.00845.x [DOI] [PubMed] [Google Scholar]
  36. Di Sabatino A., Ciccocioppo R., Luinetti O., Ricevuti L., Morera R., Cifone M. G., et al. (2003). Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis. Colon Rectum. 46, 1498–1507. 10.1007/s10350-004-6802-z [DOI] [PubMed] [Google Scholar]
  37. Ding L., Lu Z., Lu Q., Chen Y.-H. (2013). The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manage. Res. 5, 367–375. 10.2147/CMAR.S38294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Du L., Kim J. J., Shen J., Dai N. (2016). Crosstalk between inflammation and ROCK/MLCK signaling pathways in gastrointestinal disorders with intestinal hyperpermeability. Gastroenterol. Res. Pract. 2016:7374197. 10.1155/2016/7374197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ebnet K. (2017). Junctional adhesion molecules (JAMs): cell adhesion receptors with pleiotropic functions in cell physiology and development. Physiol. Rev. 97, 1529–1554. 10.1152/physrev.00004.2017 [DOI] [PubMed] [Google Scholar]
  40. Ebnet K., Suzuki A., Ohno S., Vestweber D. (2004). Junctional adhesion molecules (JAMs): more molecules with dual functions? J. Cell Sci. 117, 19–29. 10.1242/jcs.00930 [DOI] [PubMed] [Google Scholar]
  41. Elias B. C., Suzuki T., Seth A., Giorgianni F., Kale G., Shen L., et al. (2009). Phosphorylation of Tyr-398 and Tyr-402 in occludin prevents its interaction with ZO-1 and destabilizes its assembly at the tight junctions. J. Biol. Chem. 284, 1559–1569. 10.1074/jbc.M804783200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Fahlgren A., Hammarstrom S., Danielsson A., Hammarstrom M. L. (2004). beta-Defensin-3 and−4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin. Exp. Immunol. 137, 379–385. 10.1111/j.1365-2249.2004.02543.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Fasano A. (2001). Intestinal zonulin: open sesame!. Gut 49, 159–162. 10.1136/gut.49.2.159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Fasano A., Baudry B., Pumplin D. W., Wasserman S. S., Tall B. D., Ketley J. M., et al. (1991). Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc. Natl. Acad. Sci. 88, 5242–5246. 10.1073/pnas.88.12.5242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Furuse M., Hirase T., Itoh M., Nagafuchi A., Yonemura S., Tsukita S., et al. (1993). Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell Biol. 123, 1777–1788. 10.1083/jcb.123.6.1777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Furuse M., Itoh M., Hirase T., Nagafuchi A., Yonemura S., Tsukita S., et al. (1994). Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J. Cell Biol. 127, 1617–1626. 10.1083/jcb.127.6.1617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Furuse M., Sasaki H., Tsukita S. (1999). Manner of interaction of heterogeneous claudin species within and between tight junction strands. J. Cell Biol. 147, 891–903. 10.1083/jcb.147.4.891 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Gao M., Li W., Wang H., Wang G. (2013). The distinct expression patterns of claudin-10,−14,−17 and E-cadherin between adjacent non-neoplastic tissues and gastric cancer tissues. Diagn. Pathol. 8:205. 10.1186/1746-1596-8-205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Gong J., Hu M., Huang Z., Fang K., Wang D., Chen Q., et al. (2017). Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats. Front. Pharmacol. 8:42. 10.3389/fphar.2017.00042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. González-Mariscal L., Betanzos A., Ávila-Flores A. (2000). MAGUK proteins: structure and role in the tight junction. Semin. Cell Dev. Biol. 11, 315–324. 10.1006/scdb.2000.0178 [DOI] [PubMed] [Google Scholar]
  51. González-Mariscal L., Tapia R., Chamorro D. (2008). Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta 1778, 729–756. 10.1016/j.bbamem.2007.08.018 [DOI] [PubMed] [Google Scholar]
  52. Grone J., Weber B., Staub E., Heinze M., Klaman I., Pilarsky C., et al. (2007). Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1,−8 and−12. Int. J. Colorectal Dis. 22, 651–659. 10.1007/s00384-006-0197-3 [DOI] [PubMed] [Google Scholar]
  53. Groschwitz K. R., Hogan S. P. (2009). Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124, 3–20; quiz 21-2. 10.1016/j.jaci.2009.05.038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Guillemot L., Hammar E., Kaister C., Ritz J., Caille D., Jond L., et al. (2004). Disruption of the cingulin gene does not prevent tight junction formation but alters gene expression. J. Cell Sci. 117:5245. 10.1242/jcs.01399 [DOI] [PubMed] [Google Scholar]
  55. Guillemot L., Paschoud S., Pulimeno P., Foglia A., Citi S. (2008). The cytoplasmic plaque of tight junctions: a scaffolding and signalling center. Biochim. Biophys. Acta 1778, 601–613. 10.1016/j.bbamem.2007.09.032 [DOI] [PubMed] [Google Scholar]
  56. Guillemot L., Spadaro D., Citi S. (2013). The junctional proteins cingulin and paracingulin modulate the expression of tight junction protein genes through GATA-4. PLoS ONE 8:e55873. 10.1371/journal.pone.0055873 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Günzel D., Yu A. S. L. (2013). Claudins and the modulation of tight junction permeability. Physiol. Rev. 93, 525–569. 10.1152/physrev.00019.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Harhaj N. S., Antonetti D. A. (2004). Regulation of tight junctions and loss of barrier function in pathophysiology. Int. J. Biochem. Cell Biol. 36, 1206–1237. 10.1016/j.biocel.2003.08.007 [DOI] [PubMed] [Google Scholar]
  59. Heinemann U., Schuetz A. (2019). Structural features of tight-junction proteins. Int. J. Mol. Sci. 20:6020. 10.3390/ijms20236020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al. (2005). Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550–564. 10.1053/j.gastro.2005.05.002 [DOI] [PubMed] [Google Scholar]
  61. Holmberg F. E. O., Pedersen J., Jørgensen P., Soendergaard C., Jensen K. B., Nielsen O. H. (2018). Intestinal barrier integrity and inflammatory bowel disease: stem cell-based approaches to regenerate the barrier. J. Tissue Eng. Regen. Med. 12, 923–935. 10.1002/term.2506 [DOI] [PubMed] [Google Scholar]
  62. Hoover K. B., Liao S. Y., Bryant P. J. (1998). Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am. J. Pathol. 153, 1767–1773. 10.1016/S0002-9440(10)65691-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Horwitz M. S., Bradley L. M., Harbertson J., Krahl T., Lee J., Sarvetnick N. (1998). Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 4, 781–785. 10.1038/nm0798-781 [DOI] [PubMed] [Google Scholar]
  64. Hou J. (2019). Chapter 2 - paracellular channel formation, in The Paracellular Channel, ed Hou J. (Boston, MA: Academic Press; ), 9–27. 10.1016/B978-0-12-814635-4.00002-4 [DOI] [Google Scholar]
  65. Huang J., Li J., Qu Y., Zhang J., Zhang L., Chen X., et al. (2014). The expression of claudin 1 correlates with beta-catenin and is a prognostic factor of poor outcome in gastric cancer. Int. J. Oncol. 44, 1293–1301. 10.3892/ijo.2014.2298 [DOI] [PubMed] [Google Scholar]
  66. Hwang T. L., Changchien T. T., Wang C. C., Wu C. M. (2014). Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and−9 expression. Oncol. Lett. 8, 1367–1371. 10.3892/ol.2014.2295 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Ikari A., Sato T., Watanabe R., Yamazaki Y., Sugatani J. (2012). Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells. Biochim. Biophys. Acta 1823, 1110–1118. 10.1016/j.bbamcr.2012.04.005 [DOI] [PubMed] [Google Scholar]
  68. Itoh M., Bissell M. J. (2003). The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J. Mammary Gland Biol. Neoplasia 8, 449–462. 10.1023/B:JOMG.0000017431.45314.07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Jaaskelainen A., Soini Y., Jukkola-Vuorinen A., Auvinen P., Haapasaari K. M., Karihtala P. (2018). High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. BMC Cancer 18:223. 10.1186/s12885-018-4141-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Jiang H., Guan G., Zhang R., Liu G., Cheng J., Hou X., et al. (2009). Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy. Diabetes/Metab. Res. Rev. 25, 232–241. 10.1002/dmrr.940 [DOI] [PubMed] [Google Scholar]
  71. Jin Y., Blikslager A. T. (2020). The regulation of intestinal mucosal barrier by myosin light chain kinase/rho kinases. Int. J. Mol. Sci. 21:3550. 10.3390/ijms21103550 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Jiwa L. S., van Diest P. J., Hoefnagel L. D., Wesseling J., Wesseling P., Moelans C. B., et al. (2014). Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer 14:864. 10.1186/1471-2407-14-864 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Joe B., Vijaykumar M., Lokesh B. R. (2004). Biological properties of curcumin-cellular and molecular mechanisms of action. Crit. Rev. Food Sci. Nutr. 44, 97–111. 10.1080/10408690490424702 [DOI] [PubMed] [Google Scholar]
  74. Kaihara T., Kusaka T., Nishi M., Kawamata H., Imura J., Kitajima K., et al. (2003). Dedifferentiation and decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal cancer are closely related to liver metastasis. J. Exp. Clin. Cancer Res. 22, 117–123. [PubMed] [Google Scholar]
  75. Kapus A., Szászi K. (2006). Coupling between apical and paracellular transport processes. This paper is one of a selection of papers published in this Special Issue, entitled CSBMCB — Membrane Proteins in Health and Disease. Biochem. Cell Biol. 84, 870–880. 10.1139/o06-202 [DOI] [PubMed] [Google Scholar]
  76. Kidane D., Chae W. J., Czochor J., Eckert K. A., Glazer P. M., Bothwell A. L. M., et al. (2014). Interplay between DNA repair and inflammation, and the link to cancer. Crit. Rev. Biochem. Mol. Biol. 49, 116–139. 10.3109/10409238.2013.875514 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Kiela P. R., Ghishan F. K. (2009). Ion transport in the intestine. Curr. Opin. Gastroenterol. 25, 87–91. 10.1097/MOG.0b013e3283260900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Kim B. G., Lee P. H., Lee S. H., Park C. S., Jang A. S. (2018). Impact of ozone on claudins and tight junctions in the lungs. Environ. Toxicol. 33, 798–806. 10.1002/tox.22566 [DOI] [PubMed] [Google Scholar]
  79. Kim H., Lee J. M., Park J. S., Jo S. A., Kim Y. O., Kim C. W., et al. (2008). Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem. Biophys. Res. Commun. 372, 243–248. 10.1016/j.bbrc.2008.05.025 [DOI] [PubMed] [Google Scholar]
  80. Kim S. B., Chae G. W., Lee J., Park J., Tak H., Chung J. H., et al. (2007). Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Diff. 14, 982–991. 10.1038/sj.cdd.4402083 [DOI] [PubMed] [Google Scholar]
  81. Kinugasa T., Huo Q., Higashi D., Shibaguchi H., Kuroki M., Tanaka T., et al. (2007). Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Res. 27, 3729–3734. [PubMed] [Google Scholar]
  82. Komers R., Cooper M. E. (1996). Renal sodium handling in experimental diabetes: role of NO. Nephrol. Dial. Transplant. 11, 2170–2177. 10.1093/oxfordjournals.ndt.a027133 [DOI] [PubMed] [Google Scholar]
  83. Kovacs E. M. R., Mela D. J. (2006). Metabolically active functional food ingredients for weight control. Obes. Rev. 7, 59–78. 10.1111/j.1467-789X.2006.00203.x [DOI] [PubMed] [Google Scholar]
  84. Koval M. (2017). Chapter 1 - junctional interplay in lung epithelial barrier function, in Lung Epithelial Biology in the Pathogenesis of Pulmonary Disease, eds Sidhaye V. K., Koval M. (Boston, MA: Academic Press; ), 1–20. 10.1016/B978-0-12-803809-3.00001-4 [DOI] [Google Scholar]
  85. Krause G., Winkler L., Mueller S. L., Haseloff R. F., Piontek J., Blasig I. E. (2008). Structure and function of claudins. Biochem. Biophys Acta 1778, 631–645. 10.1016/j.bbamem.2007.10.018 [DOI] [PubMed] [Google Scholar]
  86. Krause G., Winkler L., Piehl C., Blasig I., Piontek J., Müller S. L. (2009). Structure and function of extracellular claudin domains. Ann. N. Y. Acad. Sci. 1165, 34–43. 10.1111/j.1749-6632.2009.04057.x [DOI] [PubMed] [Google Scholar]
  87. Kudinov A. E., Deneka A., Nikonova A. S., Beck T. N., Ahn Y.-H., Liu X., et al. (2016). Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc. Natl. Acad. Sci. U. S. A. 113, 6955–6960. 10.1073/pnas.1513616113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Lee B., Moon K. M., Kim C. Y. (2018). Tight junction in the intestinal epithelium: its association with diseases and regulation by phytochemicals. J. Immunol. Res. 2018:2645465. 10.1155/2018/2645465 [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Lee S. H. (2015). Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Int. Res. 13, 11–18. 10.5217/ir.2015.13.1.11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Lin X., Shang X., Manorek G., Howell S. B. (2013). Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4. PLoS ONE 8:e67496. 10.1371/journal.pone.0067496 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Long H., Crean C. D., Lee W. H., Cummings O. W., Gabig T. G. (2001). Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 61, 7878–7881. [PubMed] [Google Scholar]
  92. Luettig J., Rosenthal R., Barmeyer C., Schulzke J. D. (2015). Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation. Tissue Barriers 3:e977176. 10.4161/21688370.2014.977176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Ma T. Y., Boivin M. A., Ye D., Pedram A., Said H. M. (2005). Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am. J. Physiol. 288, G422–G430. 10.1152/ajpgi.00412.2004 [DOI] [PubMed] [Google Scholar]
  94. Malaguarnera G., Giordano M., Nunnari G., Bertino G., Malaguarnera M. (2014). Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J. Gastroenterol. 20, 16639–16648. 10.3748/wjg.v20.i44.16639 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Martin T. A., Lane J., Ozupek H., Jiang W. G. (2013). Claudin-20 promotes an aggressive phenotype in human breast cancer cells. Tissue Barriers 1:e26518. 10.4161/tisb.26518 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Martìn-Padura I., Lostaglio S., Schneemann M., Williams L., Romano M., Fruscella P., et al. (1998). Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J. Cell Biol. 142, 117–127. 10.1083/jcb.142.1.117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Mayangsari Y., Suzuki T. (2018a). Resveratrol ameliorates intestinal barrier defects and inflammation in colitic mice and intestinal cells. J. Agri. Food Chem. 66, 12666–12674. 10.1021/acs.jafc.8b04138 [DOI] [PubMed] [Google Scholar]
  98. Mayangsari Y., Suzuki T. (2018b). Resveratrol enhances intestinal barrier function by ameliorating barrier disruption in Caco-2 cell monolayers. J. Funct. Foods 51, 39–46. 10.1016/j.jff.2018.10.009 [DOI] [Google Scholar]
  99. Miele L., Valenza V., La Torre G., Montalto M., Cammarota G., Ricci R., et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877–1887. 10.1002/hep.22848 [DOI] [PubMed] [Google Scholar]
  100. Mogensen C. E. (1971). Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand. J. Clin. Lab. Invest. 28, 91–100. 10.3109/00365517109090667 [DOI] [PubMed] [Google Scholar]
  101. Mok K. W., Mruk D. D., Cheng C. Y. (2013). “Chapter six - regulation of blood–testis barrier (BTB) dynamics during spermatogenesis via the “Yin” and “Yang” effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2” in Int. Rev. Cell Mol. Biol., ed Jeon K. W. (Boston, MA: Academic Press; ), 291–358. 10.1016/B978-0-12-407704-1.00006-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Molina-Jijón E., Rodríguez-Muñoz R., Namorado M. D. C., Pedraza-Chaverri J., Reyes J. L. (2014). Oxidative stress induces claudin-2 nitration in experimental type 1 diabetic nephropathy. Free Rad. Biol. Med. 72, 162–175. 10.1016/j.freeradbiomed.2014.03.040 [DOI] [PubMed] [Google Scholar]
  103. Morohashi S., Kusumi T., Sato F., Odagiri H., Chiba H., Yoshihara S., et al. (2007). Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int. J. Mol. Med. 20, 139–143. 10.3892/ijmm.20.2.139 [DOI] [PubMed] [Google Scholar]
  104. Mowat A. M. (2003). Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 3, 331–341. 10.1038/nri1057 [DOI] [PubMed] [Google Scholar]
  105. Nagpal R., Newman T. M., Wang S., Jain S., Lovato J. F., Yadav H. (2018). Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J. Diabetes Res. 2018:3462092. 10.1155/2018/3462092 [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Najafian B., Mauer M. (2009). Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res. Clin. Pract. 83, 1–8. 10.1016/j.diabres.2008.08.024 [DOI] [PubMed] [Google Scholar]
  107. Németh Z., Szász A. M., Tátrai P., Németh J., Györffy H., Somorácz Á., et al. (2008). Claudin-1, −2, −3, −4, −7, −8, and −10 protein expression in biliary tract cancers. J. Histochem. Cytochem. 57, 113–121. 10.1369/jhc.2008.952291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Noda S., Tanabe S., Suzuki T. (2012). Differential effects of flavonoids on barrier integrity in human intestinal Caco-2 cells. J. Agric. Food Chem. 60, 4628–4633. 10.1021/jf300382h [DOI] [PubMed] [Google Scholar]
  109. Noda S., Tanabe S., Suzuki T. (2013). Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells. Mol. Nutr. Food Res. 57, 2019–2028. 10.1002/mnfr.201300045 [DOI] [PubMed] [Google Scholar]
  110. Noda S., Tanabe S., Suzuki T. (2014). Quercetin increases claudin-4 expression through multiple transcription factors in intestinal Caco-2 cells. J. Funct. Foods 10, 112–116. 10.1016/j.jff.2014.06.004 [DOI] [Google Scholar]
  111. Nomme J., Antanasijevic A., Caffrey M., Van Itallie C. M., Anderson J. M., Fanning A. S., et al. (2015). Structural basis of a key factor regulating the affinity between the zonula occludens first PDZ domain and claudins. J. Biol. Chem. 290, 16595–16606. 10.1074/jbc.M115.646695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Nusrat A., Parkos C. A., Verkade P., Foley C. S., Liang T. W., Innis-Whitehouse W., et al. (2000). Tight junctions are membrane microdomains. J. Cell Sci. 113:1771. 10.1242/jcs.113.10.1771 [DOI] [PubMed] [Google Scholar]
  113. Odenwald M. A., Choi W., Buckley A., Shashikanth N., Joseph N. E., Wang Y., et al. (2017). ZO-1 interactions with F-actin and occludin direct epithelial polarization and single lumen specification in 3D culture. J. Cell Sci. 130, 243–259. 10.1242/jcs.188185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Paris L., Tonutti L., Vannini C., Bazzoni G. (2008). Structural organization of the tight junctions. Biochim. Biophys. Acta 1778, 646–659. 10.1016/j.bbamem.2007.08.004 [DOI] [PubMed] [Google Scholar]
  115. Rabquer B. J., Amin M. A., Teegala N., Shaheen M. K., Tsou P.-S., Ruth J. H., et al. (2010). Junctional adhesion molecule-C is a soluble mediator of angiogenesis. J. Immunol. 185, 1777–1785. 10.4049/jimmunol.1000556 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Ram A. K., Pottakat B., Vairappan B. (2018). Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma. BMC Cancer 18:572. 10.1186/s12885-018-4484-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Rao R., Baker R., Baker S., Gupta A., Holycross M. (1997). Oxidant-induced disruption of intestinal epithelial barrier function: role of protein tyrosine phosphorylation. Am. J. Physiol. 273, G812–G823. 10.1152/ajpgi.1997.273.4.G812 [DOI] [PubMed] [Google Scholar]
  118. Rao R. K., Basuroy S., Rao V. U., Karnaky K. J., Jr., Gupta A. (2002). Tyrosine phosphorylation and dissociation of occludin–ZO-1 and E-cadherin–β-catenin complexes from the cytoskeleton by oxidative stress. Biochem. J. 368, 471–481. 10.1042/bj20011804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Ridlon J. M., Kang D. J., Hylemon P. B., Bajaj J. S. (2014). Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332–338. 10.1097/MOG.0000000000000057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Rohr M. W., Narasimhulu C. A., Rudeski-Rohr T. A., Parthasarathy S. (2019). Negative effects of a high-fat diet on intestinal permeability: a review. Adv. Nutr. 11, 77–91. 10.1093/advances/nmz061 [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Rüffer C., Gerke V. (2004). The C-terminal cytoplasmic tail of claudins 1 and 5 but not its PDZ-binding motif is required for apical localization at epithelial and endothelial tight junctions. Eur. J. Cell Biol. 83, 135–144. 10.1078/0171-9335-00366 [DOI] [PubMed] [Google Scholar]
  122. Sakakibara A., Furuse M., Saitou M., Ando-Akatsuka Y., Tsukita S. (1997). Possible involvement of phosphorylation of occludin in tight junction formation. J. Cell Biol. 137, 1393–1401. 10.1083/jcb.137.6.1393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Sallee J. L., Burridge K. (2009). Density-enhanced phosphatase 1 regulates phosphorylation of tight junction proteins and enhances barrier function of epithelial cells. J. Biol. Chem. 284, 14997–15006. 10.1074/jbc.M901901200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Schmid M., Fellermann K., Fritz P., Wiedow O., Stange E. F., Wehkamp J. (2007). Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J. Leukocyte Biol. 81, 907–915. 10.1189/jlb.0906581 [DOI] [PubMed] [Google Scholar]
  125. Shapiro L., Weis W. I. (2009). Structure and biochemistry of cadherins and catenins. Cold Spring Harb. Perspect. Biol. 1:a003053. 10.1101/cshperspect.a003053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Sheth P., Seth A., Atkinson K. J., Gheyi T., Kale G., Giorgianni F., et al. (2007). Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem. J. 402, 291–300. 10.1042/BJ20060665 [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Shigeshiro M., Tanabe S., Suzuki T. (2013). Dietary polyphenols modulate intestinal barrier defects and inflammation in a murine model of colitis. J. Funct. Foods 5, 949–955. 10.1016/j.jff.2013.02.008 [DOI] [Google Scholar]
  128. Stevens Y., Rymenant E. V., Grootaert C., Camp J. V., Possemiers S., Masclee A., et al. (2019). The intestinal fate of citrus flavanones and their effects on gastrointestinal health. Nutrients 11:71464. 10.3390/nu11071464 [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Stevenson B. R., Siliciano J. D., Mooseker M. S., Goodenough D. A. (1986). Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell Biol. 103, 755–766. 10.1083/jcb.103.3.755 [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Strugala V., Dettmar P. W., Pearson J. P. (2008). Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int. J. Clin. Pract. 62, 762–769. 10.1111/j.1742-1241.2007.01665.x [DOI] [PubMed] [Google Scholar]
  131. Suh Y., Yoon C. H., Kim R. K., Lim E. J., Oh Y. S., Hwang S. G., et al. (2013). Claudin-1 induces epithelial–mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32, 4873–4882. 10.1038/onc.2012.505 [DOI] [PubMed] [Google Scholar]
  132. Sun L., Xu C., Chen G., Yu M., Yang S., Qiu Y., et al. (2015). A novel role of OS-9 in the maintenance of intestinal barrier function from hypoxia-induced injury via p38-dependent pathway. Int. J. Biol. Sci. 11, 664–671. 10.7150/ijbs.10783 [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Suren D., Yildirim M., Kaya V., Alikanoglu A. S., Bulbuller N., Yildiz M., et al. (2014). Loss of tight junction proteins (Claudin 1, 4, and 7) correlates with aggressive behavior in colorectal carcinoma. Med. Sci. Monit. 20, 1255–1262. 10.12659/MSM.890598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Suzuki T. (2013). Regulation of intestinal epithelial permeability by tight junctions. Cell. Mol. Life Sci. 70, 631–659. 10.1007/s00018-012-1070-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Suzuki T. (2020). Regulation of the intestinal barrier by nutrients: the role of tight junctions. Anim. Sci. J. 91:e13357. 10.1111/asj.13357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Suzuki T., Hara H. (2009). Quercetin enhances intestinal barrier function through the assembly of zonnula occludens-2, occludin, and claudin-1 and the expression of claudin-4 in caco-2 cells. J. Nutr. 139, 965–974. 10.3945/jn.108.100867 [DOI] [PubMed] [Google Scholar]
  137. Suzuki T., Hara H. (2010). Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr. Metab. 7:19. 10.1186/1743-7075-7-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Suzuki T., Tanabe S., Hara H. (2010). Kaempferol enhances intestinal barrier function through the cytoskeletal association and expression of tight junction proteins in Caco-2 cells. J. Nutr. 141, 87–94. 10.3945/jn.110.125633 [DOI] [PubMed] [Google Scholar]
  139. Suzuki T., Yoshinaga N., Tanabe S. (2011). Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J. Biol. Chem. 286, 31263–31271. 10.1074/jbc.M111.238147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Takeichi M. (1988). The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 102, 639–655. 10.1242/dev.102.4.639 [DOI] [PubMed] [Google Scholar]
  141. Tornavaca O., Chia M., Dufton N., Almagro L. O., Conway D. E., Randi A. M., et al. (2015). ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. J. Cell Biol. 208, 821–838. 10.1083/jcb.201404140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Tsukita S., Furuse M., Itoh M. (2001). Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2, 285–293. 10.1038/35067088 [DOI] [PubMed] [Google Scholar]
  143. Turner J. R. (2006). Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am. J. Pathol. 169, 1901–1909. 10.2353/ajpath.2006.060681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Umeda K., Ikenouchi J., Katahira-Tayama S., Furuse K., Sasaki H., Nakayama M., et al. (2006). ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 126, 741–754. 10.1016/j.cell.2006.06.043 [DOI] [PubMed] [Google Scholar]
  145. Umeda K., Matsui T., Nakayama M., Furuse K., Sasaki H., Furuse M., et al. (2004). Establishment and characterization of cultured epithelial cells lacking expression of ZO-1. J. Biol. Chem. 279, 44785–44794. 10.1074/jbc.M406563200 [DOI] [PubMed] [Google Scholar]
  146. Usami Y., Chiba H., Nakayama F., Ueda J., Matsuda Y., Sawada N., et al. (2006). Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Human Pathol. 37, 569–577. 10.1016/j.humpath.2005.12.018 [DOI] [PubMed] [Google Scholar]
  147. van Roy F., Berx G. (2008). The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 65, 3756–3788. 10.1007/s00018-008-8281-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Visser J., Rozing J., Sapone A., Lammers K., Fasano A. (2009). Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann. N. Y. Acad. Sci. 1165, 195–205. 10.1111/j.1749-6632.2009.04037.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Wang J., Ghosh S. S., Ghosh S. (2017). Curcumin improves intestinal barrier function: modulation of intracellular signaling, and organization of tight junctions. Am. J. Physiol. 312, C438–C445. 10.1152/ajpcell.00235.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Wehkamp J., Fellermann K., Herrlinger K. R., Baxmann S., Schmidt K., Schwind B., et al. (2002). Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 14, 745–752. 10.1097/00042737-200207000-00006 [DOI] [PubMed] [Google Scholar]
  151. Wibowo A. A., Pardjianto B., Sumitro S. B., Kania N., Handono K. (2019). Decreased expression of MUC2 due to a decrease in the expression of lectins and apoptotic defects in colitis patients. Biochem. Biophys. Rep. 19:100655. 10.1016/j.bbrep.2019.100655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Williams C. S., Zhang B., Smith J. J., Jayagopal A., Barrett C. W., Pino C., et al. (2011). BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. J. Clin. Invest. 121, 4056–4069. 10.1172/JCI44228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Yamagata K., Nammo T., Moriwaki M., Ihara A., Iizuka K., Yang Q., et al. (2002). Overexpression of dominant-negative mutant hepatocyte nuclear factor-1α in pancreatic β-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced β-cell proliferation, and diabetes. Diabetes 51:114. 10.2337/diabetes.51.1.114 [DOI] [PubMed] [Google Scholar]
  154. Ye D., Ma I., Ma T. Y. (2006). Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G496–504. 10.1152/ajpgi.00318.2005 [DOI] [PubMed] [Google Scholar]
  155. Yoon C.-H., Kim M.-J., Park M.-J., Park I.-C., Hwang S.-G., An S., et al. (2010). Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J. Biol. Chem. 285, 226–233. 10.1074/jbc.M109.054189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Yuan D., Sun G., Zhang R., Luo C., Ge M., Luo G., et al. (2015). Connexin 43 expressed in endothelial cells modulates monocyte-endothelial adhesion by regulating cell adhesion proteins. Mol. Med. Rep. 12, 7146–7152. 10.3892/mmr.2015.4273 [DOI] [PubMed] [Google Scholar]
  157. Yuan Y., Naito H., Jia X., Kitamori K., Nakajima T. (2017). Combination of hypertension along with a high fat and cholesterol diet induces severe hepatic inflammation in rats via a signaling network comprising NF-κB, MAPK, and Nrf2 Pathways. Nutrients 9:33. 10.20944/preprints201707.0033.v1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Zeissig S., Bürgel N., Günzel D., Richter J., Mankertz J., Wahnschaffe U., et al. (2007). Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56:61. 10.1136/gut.2006.094375 [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Zhang M., Long Y., Sun Y., Wang Y., Li Q., Wu H., et al. (2011). Evidence for the complementary and synergistic effects of the three-alkaloid combination regimen containing berberine, hypaconitine and skimmianine on the ulcerative colitis rats induced by trinitrobenzene-sulfonic acid. Eur. J. Pharmacol. 651, 187–196. 10.1016/j.ejphar.2010.10.030 [DOI] [PubMed] [Google Scholar]
  160. Zhang R., Xu J., Zhao J., Chen Y. (2017). Genistein improves inflammatory response and colonic function through NF-κB signal in DSS-induced colonic injury. Oncotarget 8, 61385–61392. 10.18632/oncotarget.18219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Zhang Z., Wang A., Sun B., Zhan Z., Chen K., Wang C. (2013). Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. J. Cardiothorac. Surg. 8:95. 10.1186/1749-8090-8-95 [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Zhu H. Q., Wang X. B., Han J. X., Hu Z. P., Wang Y., Zhou Q., et al. (2013). Myosin light chain kinase inhibitor attenuates atherosclerosis and permeability via reduced endothelial tight junction in rabbits. Int. J. Cardiol. 168, 5042–5043. 10.1016/j.ijcard.2013.07.219 [DOI] [PubMed] [Google Scholar]
  163. Zhu L., Han J., Li L., Wang Y., Li Y., Zhang S. (2019). Claudin family participates in the pathogenesis of inflammatory bowel diseases and colitis-associated colorectal cancer. Front. Immunol. 10:1441. 10.3389/fimmu.2019.01441 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Physiology are provided here courtesy of Frontiers Media SA

RESOURCES